Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Oramed Pharmaceuticals, Inc.
Healthcare
P/NCAV
0.9x
Ticker
ORMP
Exchange
NASDAQ
Country
United States
Close
2.35 $
Mkt Cap
95.3M $
EV
137.3M $
NCAV Burn Rate
28.1%
Current Ratio
3.06
Debt/Equity
0.31
EV/REV
102.46x
EV/EBIT
-8.7x
EV/FCF
-13.7x
Dilution
15.8% p.A
Total Net Income
-132.2M $
Cheapness
100.0%
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average